Shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX - Get Free Report) were up 27.3% on Friday . The stock traded as high as $19.51 and last traded at $19.37. Approximately 510,895 shares were traded during mid-day trading, an increase of 920% from the average daily volume of 50,104 shares. The stock had previously closed at $15.22.
Neoleukin Therapeutics Stock Performance
The firm's 50-day moving average is $13.44 and its two-hundred day moving average is $20.66. The stock has a market cap of $182.04 million, a P/E ratio of -6.23 and a beta of 1.11.
About Neoleukin Therapeutics
(
Get Free Report)
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Neoleukin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neoleukin Therapeutics wasn't on the list.
While Neoleukin Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
